1 Table of Contents 1.1 List of Figures 1.2 List of Tables 2 Industry Overview 2.1 Principles of Diagnostic X-ray Imaging 2.2 CT Contrast Media 2.2.1 Overview 2.2.2 Positive Contrast Media 2.2.3 Negative Contrast Media 2.3 Principles of Diagnostic Magnetic Resonance Imaging 2.4 MRI Contrast Media 2.4.1 Overview 2.4.2 Biodistribution 2.5 Principles of Diagnostic Ultrasound Imaging 2.6 Ultrasound Contrast Media 2.6.1 Overview 2.7 Safety Considerations 2.7.1 General Safety 2.7.2 Viscosity 2.7.3 Osmolality 2.7.4 Strength 2.7.5 Linear Versus Macrocyclic 2.7.6 Ultrasound Contrast Safety 2.8 Market Access and Reimbursement 2.8.1 US 2.9 Market Volume 2.9.1 US 3 Competitive Assessment 3.1 Overview 3.2 CT Contrast Media 3.2.1 Overview 3.3 MRI Contrast Media 3.3.1 Overview 3.4 Ultrasound Contrast Media 3.4.1 Overview (Microbubbles) 3.5 Company Share Analysis 3.5.1 Global 3.5.2 North America 4 Pipeline Products 4.1 Overview 4.2 CT Contrast Media-Pipeline Products 4.2.1 Overview 4.3 MRI Contrast Media-Pipeline Products 4.3.1 Overview 4.4 Ultrasound Contrast Media-Pipeline Products 4.4.1 Overview 5 Mergers and Acquisitions 5.1 Guerbet and Mallinckrodt 6 Current and Future Players 6.1 Trends in Corporate Strategy 6.2 Company Profiles 6.2.1 AGFA Healthcare (Agfa-Gevaert) 6.2.2 AMAG Pharmaceuticals 6.2.3 Bayer 6.2.4 Bracco 6.2.5 GE Healthcare 6.2.6 Guerbet/Mallinckrodt 6.2.7 Lantheus Medical Imaging 6.2.8 Sanochemia 6.2.9 Other Companies 7 Market Drivers, Barriers, and Unmet Needs 7.1 Market Drivers 7.1.1 World’s Rising and Aging Population 7.1.2 Increased Disease Screening Practices 7.1.3 Rising Prevalence of Disease 7.1.4 Increased Financial Power of Developing Countries 7.1.5 Mainstay of Modern Medicine 7.1.6 Power Injectors and Prefilled Contrast Delivery 7.1.7 Ultrasound Contrast Media 7.2 Barriers 7.2.1 Safety Issues 7.2.2 Price Competition 7.2.3 Limited Innovation 7.2.4 The Price of Ultrasound Contrast Media 7.2.5 Alternative or More Powerful Imaging Modalities 7.2.6 Generic Contrast Media 7.3 Unmet Needs 7.3.1 Lower Injection Volumes 7.3.2 Reduced Adverse Reactions 7.3.3 New Contrast Media 8 Market Outlook and Forecast 8.1 US 8.1.1 Contrast Media Market by Segment 8.1.2 CT Contrast Media Market by Sub-segment 9 Appendix 9.1 Bibliography 9.2 Abbreviations 9.3 Report Methodology 9.3.1 Overview 9.3.2 Coverage 9.3.3 Primary Research-Key Opinion Leader Interviews 9.3.4 Primary Research Interviews-Physician and Industry Participants 9.3.5 Physician Survey 9.3.6 Expert Panel Validation 9.3.7 Secondary Research 9.4 Forecasting Methodology 9.5 About the Team 9.5.1 Analysts 9.5.2 David Brady, Director of Operations - Market Research 9.5.3 Tyler Fletcher, Global Head of Medical Devices 9.6 Contact Us 9.7 Disclaimer

1.1 List of Figures Table 1: Molecular Structure of CT Contrast Media Table 2: Paramagnetic and Superparamagnetic Media Table 3: Contrast Medium Reactions Table 4: Specification of Iodinated Contrast Media Table 5: US Contrast Media Market Volume by Segment, 2012-2022 Table 6: US CT Contrast Media Market Volume by Sub-segment, 2012-2022 Table 7: Marketed Ionic Iodinated CT Products Table 8: Marketed Non-Ionic CT Products Table 9: Marketed Barium Contrast Media Products Table 10: Marketed Paramagnetic Media Table 11: Marketed Superparamagnetic Media Table 12: Marketed Ultrasound Media Table 13: CT Contrast Media-Pipeline Products Table 14: MRI Contrast Media-Pipeline Products Table 15: Ultrasound Contrast Media-Pipeline Products Table 16: Company Profile-AGFA Healthcare Table 17: AGFA Healthcare’s Featured Contrast Media Products Table 18: SWOT Analysis-AGFA Healthcare Table 19: Company Profile-AMAG Pharmaceuticals Table 20: AMAG Pharmaceuticals’ Featured Contrast Media Products Table 21: SWOT Analysis-AMAG Pharmaceuticals Table 22: Company Profile-Bayer AG Table 23: Bayer’s Featured Contrast Media Products Table 24: SWOT Analysis-Bayer Table 25: Company Profile-Bracco Table 26: Bracco’s Featured Contrast Media Products Table 27: SWOT Analysis-Bracco Table 28: Company Profile-GE Healthcare Table 29: GE Healthcare Featured Contrast Media Products Table 30: SWOT Analysis-GE Healthcare Table 31: Company Profile-Guerbet (post-Mallinckrodt acquisition) Table 32: Guerbet’s Featured Contrast Media Products (post-Mallinckrodt acquisition) Table 33: SWOT Analysis-Guerbet Table 34: Company Profile-Lantheus Medical Imaging Table 35: Lantheus Medical Imaging’s Featured Contrast Media Products Table 36: SWOT Analysis-Lantheus Medical Imaging Table 37: Company Profile-Sanochemia Table 38: Sanochemia’s Featured Contrast Media Products Table 39: SWOT Analysis-Sanochemia Table 40: Other Companies in the Contrast Media Market Table 41: US Contrast Media Market Value ($M) by Segment, 2012-2022 Table 42: US CT Contrast Media Market Value ($M) by Sub-segment, 2012-2022 Table 43: Primary Research Interviews Completed Table 44: Physicians Surveyed, By Country 1.2 List of Tables Figure 1: Electromagnetic Spectrum Figure 2: X-ray Scan of the Ankle Figure 3: Double Contrast Enhancement of the GI Tract Figure 4: Negative Contrast Enhancement of the Stomach Figure 5: Structure of Gadolinium Figure 6: Ultrasound Imaging Figure 7: Ultrasound Depth Versus Resolution Figure 8: Structure of Linear and Macrocyclic Media Figure 9: US Contrast Media Market Volume by Segment, 2012-2022 Figure 10: US CT Contrast Media Market Volume by Sub-segment, 2012-2022 Figure 11: US Contrast Media Market Volume Percentage Breakdown by Sub-segment, 2015 and 2022 Figure 12: Global Company Share, Contrast Media, 2014 Figure 13: North America Company Share, Contrast Media, 2014 Figure 14: US Contrast Media Market Value ($M) by Segment, 2012-2022 Figure 15: US CT Contrast Media Market Value ($M) by Sub-segment, 2012-2022 Figure 16: US CT Contrast Media Market Percentage Breakdown by Sub-segment, 2015 and 2022

AGFA Healthcare (Agfa-Gevaert) AMAG Pharmaceuticals Bayer Bracco GE Healthcare Guerbet/Mallinckrodt Lantheus Medical Imaging Sanochemia